Revised SPC: Kenalog (triamcinolone acetonide) Intra-articular/Intramuscular Injection

Blurred vision has been added as adverse effect and SPC updated to advise that visual disturbance may be reported with systemic/topical corticosteroid use and if a patient presents with such symptoms, they should be considered for referral to an ophthalmologist for evaluation.

Source:

electronic Medicines compendium